Manufacturers tell Congress that Covid vaccine volume in U.S. will increase significantly next month

Lillie McCray (R) will receive the Pfizer-BioNTech vaccine against corfavirus disease (COVID-19) from health professional Ghassan Ayyad (L) Walgreens at the Victor Walchirk Apartments in Evanston, Illinois, on February 22, 2021.

Kamil Krzaczynski | Reuters

The supply of Covid-19 vaccine in the United States is expected to increase significantly next month, with manufacturers doubling the pace of production, executives said in prepared remarks to Congress on Tuesday.

Pfizer expects to deliver more than 13 million doses of two-shot vaccine per week to the U.S. by mid-March, more than double the number of weekly doses the company sent earlier this month, said John Young, Pfizer’s chief business officer. witness. The testimony was issued before the House Energy and Trade Committee was heard.

Young also said Pfizer is well on its way to delivering 120 million doses by the end of March and an additional 80 million doses to be released by the end of May.

Dr. Modhen President Dr. Stephen Hoge said Hoge’s prepared testimony says his company is working similarly to double its shipments to the U.S. by April. Moderna hopes to deliver 40 million servings a month, which will roughly double the current rate, he said.

“Since the end of 2020, we’ve doubled our monthly deliveries to the U.S. government, and we’re working to double them again by April, to more than 40 million servings a month,” Hoge said. “As we work to achieve these goals, we are constantly learning and working closely with our partners and the federal government to identify ways to address bottlenecks and accelerate our production.”

In the document, he added that if the Food and Drug Administration authorized the company to add multiple doses of vaccine to each vial, it would “improve emissions.”

U.S. supply is also expected to be helped by the entry of new manufacturers. The FDA is scheduled to review Johnson & Johnson single-dose vaccination on Thursday. Dr. Richard Nettles, J&J’s vice president of medicine, said in a prepared statement that the company plans to ship more than 20 million doses to the United States by the end of March.

Nettle added that the company is confident it will deliver 100 million servings in the first half of the year.

Overall, the comments show that the United States is well on its way to having received 240 million doses of vaccine by the end of March, enough to vaccinate about 130 million people.

This can be a huge benefit of introducing a vaccine. State and local officials said the biggest constraint was supplying federal government rations. According to the Center for Disease Prevention and Control, more than 75.2 million doses have been delivered to states and more than 64.1 million doses have been delivered.

The scheduled time for the house hearing is ET 10:30.